VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI) is pleased to announce that Erinn B. Broshko, Chief Executive Officer, will be presenting at BioContact Québec 2006 ( www.biocontact.qc.ca) in Québec City. BioContact is a biopharmaceutical partnership symposium with over 1200 participants.

The 30 minute presentation will be followed by a question and answer session and will take place on Thursday, October 5, 2006 at 3:30 p.m. at the Château Frontenac.

About Med BioGene

MBI is a biotechnology company with advanced research and development in gene expression technology. MBI is utilizing its expertise in gene expression to identify those genes, known as "biomarkers," which mark the presence of certain cancers and cardiovascular disease.

These biomarkers will be used as an effective tool for disease diagnosis and to unlock innovation in therapeutic development and treatment. With a robust set of qualified biomarkers, disease diagnosis will be quicker, less invasive and more accurate. Moreover, the safety and effectiveness of new therapeutics will be enhanced, drug products will get to patients in less time and treatment decisions will be tailored more effectively to the needs of each patient. In short, MBI is at the forefront of personalized medicine.

MBI is currently focused on developing biomarkers for lymphoma and leukemia through its Hematological Cancer Profiling System™, and for cardiovascular disease through its Cardiovascular Disease Profiling System™.

For further information, please contact:

Erinn B. Broshko
Chief Executive Officer
(604) 827-4505
ebroshko@medbiogene.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.